Advertisement
Financing › Details
Oxford Genetics–WuXi PharmaTech: investment, 202103 acquisition 100% of Oxford Genetics Ltd by WuXi Advanced Therapies
Period | 2021-03-02 | |
Money taker | Oxford Genetics Ltd. (Oxgene) | |
Product | TESSA technology for adeno-associated viral (AAV) manufacturing | |
Person | Chang, David (WuXi PharmaTech 202103 CEO of WuXi ATU) | |
Oxford Genetics Ltd.. (3/2/21). "Press Release: WuXi AppTec Completes Acquisition of Oxgene to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers". Philadeliphia, PA & Oxford.
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit. WuXi ATU’s integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU’s first facility in Europe and will further enhance these industry-leading capabilities.
Since its founding in 2011, OXGENE has offered discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions. It also provides manufacturing systems that deliver exceptional scalability. OXGENE’s novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing simplify cell and gene therapy manufacturing while significantly reducing costs.
“OXGENE is proud to have invented a range of next-generation platforms that address the complexities of viral vector manufacturing for gene and cell therapies,” said Dr. Ryan Cawood, Founder and Chief Executive Officer of OXGENE. “We are excited to join the team at WuXi ATU and to work together to scale up our technologies as a combined business, which will strengthen and broaden our service offerings for customers, improving by orders of magnitude the scale and cost of bringing cell and gene therapies to market. The benefits will be significant for the industry and for patients worldwide.”
“We are delighted to welcome OXGENE to WuXi ATU,” said Dr. David Chang, Chief Executive Officer of WuXi ATU. “By combining WuXi ATU’s world-class cell and gene therapy CTDMO platform with OXGENE’s innovative capabilities, we will be able to provide transformative solutions for our customers. This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally.”
ENDS
About WuXi Advanced Therapies
As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies (WuXi ATU) is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit www.advancedtherapies.com
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.” Please visit: www.wuxiapptec.com
Media Contact:
Davy Wu
mediainquiries@wuxiapptec.com
Jocelyne Bath
media@oxgene.com
Customer Contact:
Min Park
atu.info@wuxiapptec.com
Investor Contact:
Tianyi Zhang
zhang_tianyi0101@wuxiapptec.com
Record changed: 2022-01-02 |
Advertisement
More documents for WuXi PharmaTech (Group)
- [1] Metrion Biosciences Ltd.. (7/26/21). "Press Release: Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development". Cambridge....
- [2] Oxford Genetics Ltd.. (3/2/21). "Press Release: WuXi AppTec Completes Acquisition of Oxgene to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers". Philadeliphia, PA & Oxford....
- [3] Genomics Medicine Ireland Ltd.. (8/12/19). "Press Release: Genomics Medicine Ireland Announces Strategic Advisory Board"....
- [4] Sphere Fluidics Ltd.. (2/18/19). "Press Release: Oxford Genetics and Sphere Fluidics Announce a Multi-partner Collaboration to Expedite the Development of Automated Microfluidic Systems for Rapid and High-throughput Gene Editing in Mammalian Cell Lines"....
- [5] Oxford BioTherapeutics Ltd.. (12/11/18). "Press Release: Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody Platform for Five Bispecific Antibody Programs for up to $450 Million". Shanghai & Oxford....
- [6] Genomics Medicine Ireland Ltd.. (11/27/18). "Press Release: $400 Million Investment Programme Positions Ireland for Global Leadership in Genomic Research and Advanced Life Sciences"....
- [7] Genomics Medicine Ireland Ltd.. (11/7/18). "Press Release: GMI Genomics Centre Awarded CAP-Accreditation"....
- [8] Genomics Medicine Ireland Ltd.. (11/6/18). "Press Release: GMI Appoints Dr. Anne Jones as CEO"....
- [9] Oxford Genetics Ltd.. (9/20/18). "Press Release: Oxford Genetics Extends Its CRISPR Gene Editing Technology License Agreement from ERS Genomics to Support Its Growth Internationally". Oxford....
- [10] Genomics Medicine Ireland Ltd.. (8/30/18). "Press Release: Genomics Medicine Ireland and University of Cambridge Announce Multiple Sclerosis Research Collaboration". Dublin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top